Lotefast Ophthalmic Suspension contains Loteprednol etabonate 0.5% w/v, a corticosteroid indicated for the treatment of inflammatory conditions of the eye, including allergic conjunctivitis, postoperative inflammation, and anterior uveitis. Loteprednol etabonate is a corticosteroid designed to reduce inflammation by inhibiting the release of inflammatory mediators and suppressing the migration of polymorphonuclear leukocytes, thereby alleviating symptoms such as redness, swelling, and discomfort. The ophthalmic suspension formulation ensures targeted delivery to the ocular tissues, maximizing therapeutic efficacy while minimizing systemic absorption. Lotefast is typically administered as one to two drops into the affected eye(s) four times daily, with dosage adjustments based on clinical response and severity of the condition. Caution is advised in patients with a history of glaucoma, as corticosteroids may increase intraocular pressure. Prolonged use should be avoided unless closely monitored by an ophthalmologist to prevent potential adverse effects such as cataract formation or secondary ocular infections. Patients should be instructed to avoid contamination of the dropper tip and to discontinue use if signs of ocular infection or hypersensitivity develop. Lotefast Ophthalmic Suspension offers an effective option for managing ocular inflammation with a favorable safety profile when used as directed.